Characterization of diphenyl phthalate as an agonist for estrogen receptor: an in vitro and in silico study. (4th May 2022)

• Record Type: Journal Article
• Authors: Lv, Chengyu; Wei, Zhengyi; Yue, Benjie; Xia, Ning; Huang, Wei; Yue, Yulan; Li, Zhuolin; Li, Tiezhu; Zhang, Xiuxia; Wang, Yongjun
• Is Part Of: Toxicology mechanisms and methods. Volume 32:Number 4(2022)
• Page Start: 280
• Page End: 287
• Publication Date: 2022-05-04
• Subjects: Phthalate esters -- estrogen receptor -- endocrine disruption -- estrogen activity; Analytical toxicology -- Periodicals; Toxicology -- Periodicals; Toxicology -- Methodology -- Periodicals; 615.907
• DOI: 10.1080/15376516.2021.1998276
• Languages: English
• ISSNs: 1537-6516

Abstract

Abstract: Phthalate esters (PAEs) are important pollutants in the environment, which can interfere with the endocrine system by mimicking estrogen. However, limited information is available on modulating the estrogen receptor (ER) of five PAEs including di (2-ethylhexyl) phthalate (DEHP), diisononyl phthalate (DINP), benzyl butyl phthalate (BBP), diphenyl phthalate (DPhP) and dicyclohexyl phthalate (DCHP). This study evaluated the agonistic effects of PAEs on human ER. The cytotoxicity assay showed that there were a significant inhibition of the cell proliferation with treatment of five PAEs. Moreover, DPhP does-dependently enhanced ER-mediated transcriptional activity in the reporter gene assay. The increased expression of estrogen-responsive genes ( TFF1, CTSD, and GREB1 ) was also observed in MCF-7 cells treated with DPhP. The result of molecular docking showed that DPhP tended to bind to the agonist conformation of ER compared with the antagonist conformation of ER, demonstrating its agonist characteristic that has been confirmed in the reporter gene assay. Thus, we found that DPhP may be evaluated as an ER agonist in vitro and it can interfere with the normal function of human ER.